Ciclocur

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ciclocur

Property Description
Active ingredient Estradiol Valerate, Levonorgestrel
Form Sequential Oral Tablets (Coloured and White)
Pharmacological class Combined Hormonal Contraceptive (CHC)
Common use Contraception (Prevention of Pregnancy)
Origin Synthetic and Semisynthetic

What Type of Medicine is Ciclocur?

Ciclocur is classified as a Combined Hormonal Contraceptive (CHC), an established type of prescription medication delivered via oral tablets. It is recognized as an Estrogen-Progestin Combination drug, a class recognized for its effectiveness in fertility management. The general purpose of this medication is contraception, providing reliable and effective pregnancy prevention for females of reproductive potential. Combined estrogen and progestin formulations serve an essential role as a primary method of fertility regulation.

Composition and Origin: Estradiol Valerate and Levonorgestrel

The active constituents in Ciclocur are Estradiol Valerate and Levonorgestrel. The use of Estradiol Valerate is a differentiating factor, as it functions as a precursor that the body metabolizes into natural estradiol, distinct from purely synthetic estrogens used in some other formulations. Levonorgestrel is the synthetic hormonal component, belonging to the progestin class, widely clinically recognized for its anti-ovulatory properties. The medication is formulated as a course of distinct Coloured Tablets and White Tablets, specifically designed for a sequential dosing regimen. This feature is crucial for its controlled release profile, offering a structured approach to hormonal intake over the cycle.

General Purpose and Mechanism Principles

The core purpose of the combination of Estradiol Valerate and Levonorgestrel is to prevent pregnancy through systemic hormone balance modulation. This is achieved predominantly by suppressing the natural hormonal signals required to trigger ovulation. Additionally, the presence of Levonorgestrel induces changes, such as the thickening of the cervical mucus, which further impedes the passage of sperm. This dual pharmacological strategy, utilizing both an estrogen and progestin in a structured sequence, ensures a high level of contraceptive effectiveness.

What side effects are possible with Ciclocur?

Possible Side Effects and Safety Information

The safety profile of Ciclocur is established through official regulatory documentation, which categorizes adverse reactions based on their frequency and clinical significance.

Adverse Reactions

The majority of side effects are categorized as Very Common (occurring in 1 in 10 people or more) or Common (occurring in up to 1 in 10 people). These commonly reported reactions frequently involve the gastrointestinal and nervous systems. Specifically, Headache and Nausea are classified as Very Common, while Diarrhea and Dizziness are classified as Common.

Less frequently reported reactions, such as Vomiting and Rash, are categorized as Uncommon.

Serious and Clinically Significant Risks

Official prescribing information highlights that certain serious adverse reactions may require the immediate discontinuation of Ciclocur. These include severe immune system disorders such as Anaphylactic Reaction/Shock and severe hepatic events like Hepatitis (liver injury). These serious reactions are generally classified in the Rare frequency band.

In the event of signs of liver dysfunction, treatment must be discontinued and liver function must be monitored. Patients with known hypersensitivity to the drug's components must not use Ciclocur (contraindication).

Population and Dose Considerations

Safety notes emphasize the need for caution and monitoring in specific patient populations:

  • Renal Impairment: Ciclocur is contraindicated in cases of severe uncompensated renal failure, and dose adjustments are necessary in less severe impairment due to the risk of drug accumulation.
  • Dose-Related: The incidence of gastrointestinal issues, such as nausea and diarrhea, has been observed to be dose-dependent, increasing at higher therapeutic doses.
  • Monitoring: Periodic assessment of renal function is required during extended use. Use requires close monitoring in individuals with a history of cardiovascular disease or seizures.

Overdose and Emergency Response

Overdose and when to seek help

This section outlines the official, regulator-documented information regarding overdosage with Ciclocur (Estradiol Valerate, Levonorgestrel).


Overdose Scope

Feature Official Regulatory Statement
Documented Overdose Presentations Symptoms include nausea, vomiting, and withdrawal bleeding in females.
Physiological Systems Affected Primarily gastrointestinal and reproductive.
Population-Specific Overdose Notes Ingestion by children has been specifically evaluated and is associated with no reports of serious ill effects.
Emergency-Response Statements Seek immediate medical help or Contact a Poison Control Center immediately.
When Immediate Medical Help is Required Immediate medical attention is required upon known or suspected overdosage for professional assessment and supportive care.

Overdose Classifications (High-Level)

Classification Official Regulatory Statement
Severity Classification No serious ill effects have been reported; the overdose is generally not likely to be life-threatening.
Overdose-Context Constraints No specific antidote is known. Management must be restricted to symptomatic and supportive treatment.

Resulting Overdose Structure

Official Overdose Statements:

  • Overdosage is associated with clinical manifestations including nausea, vomiting, and withdrawal bleeding in females.
  • There are no reports of serious ill effects or life-threatening outcomes documented in the event of acute overdosage.
  • Immediate medical help must be sought or a Poison Control Center contacted immediately upon suspected or confirmed overdose.
  • No specific antidote is known, meaning management is limited to symptomatic and supportive treatment.

Connection to the overall overdose profile: Regulatory documents define the Ciclocur overdose profile as typically presenting with gastrointestinal and gynecological symptoms, with an official classification of minimal acute toxicity regarding severe outcomes. The documented need to seek immediate medical help is a mandatory action for assessment and supportive treatment, reflecting that no specific pharmacological intervention is available or documented in the labeling.

Therapeutic Uses of Ciclocur

Ciclocur is a combined hormonal medication commonly used for pregnancy prevention. Its hormonal composition supports the management of a range of symptoms related to physical discomfort and systemic imbalance. The treatment offers symptomatic relief that helps patients cope more steadily with difficult episodes and may assist with maintaining a sense of stability when symptoms become more noticeable.


Therapeutic Uses and Patient Benefit

This medication is commonly used to help with managing symptoms of severe menstrual cramps (dysmenorrhea), excessive menstrual blood loss (menorrhagia), and hormonal acne. It is also relevant for easing conditions characterized by episodic or fluctuating manifestations, such as the irregular cycles associated with Polycystic Ovary Syndrome (PCOS).

Quick Fact: Relief for Disruptive Symptoms Ciclocur provides supportive relief when symptoms interfere with routine activities, contributing to easing discomfort during periods of heightened symptoms.

“The medication may assist with achieving a more regular and predictable menstrual pattern, which is commonly used for long-term reproductive planning.”

This comprehensive support helps ease day-to-day comfort and supports general well-being during symptomatic phases.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Ciclocur?

The eligibility for Ciclocur, a Combined Hormonal Contraceptive (Estradiol Valerate and Levonorgestrel), is strictly defined by regulatory guidelines to ensure safe use, focusing on preventing serious cardiovascular and thromboembolic risks.

Eligibility Scope

Category Regulatory Status
Populations Allowed Females of reproductive potential.
Populations Contraindicated Females over age 35 who smoke.
Physiological Status Contraindicated in known or suspected pregnancy.
Postpartum Restriction Start no earlier than 4 weeks after delivery (non-breastfeeding).
Age Restriction Not indicated for use in postmenopausal women or before menarche.

Official Contraindications

The medicine is formally contraindicated in individuals with a high risk of arterial or venous thrombotic diseases, including a history of Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), or cerebrovascular disease. Other absolute exclusions include current or history of hormone-sensitive cancers (such as breast cancer), severe liver disease, liver tumors, uncontrolled hypertension, and diabetes with vascular complications.

Conditional Use

Use is generally not recommended while breastfeeding, and patients with well-controlled hypertension require regular monitoring.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section outlines the formally documented interaction patterns for combined hormonal contraceptives containing Estradiol Valerate and Levonorgestrel, as recognized by governmental regulatory authorities.


Interaction Scope

Category Official Regulatory Statement
Medicinal product categories with documented interactions Enzyme-Inducing Medicines (e.g., strong CYP3A4 inducers); Hepatitis C combination Antivirals; Anticonvulsants; Specific Antibiotics; Immunosuppressants (affected by the CHC).
Specific interacting medicines (if explicitly listed) Combinations of antivirals, including Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir; Phenytoin; Carbamazepine; Rifampicin; Lamotrigine; Cyclosporine; Theophylline.
Mechanistic basis of interactions (only if stated in label) Enzyme Induction (Increased metabolism of the hormones, primarily via CYP3A4); Glucuronidation Enhancement (Estrogen component increases clearance of certain co-administered drugs); Enzyme Inhibition (CHC may increase co-administered drug levels).
Interaction-related restrictions Discontinuation is required before initiating specific Hepatitis C combination therapies. Non-hormonal backup or an alternative contraceptive method is recommended during co-administration with enzyme-inducing medicines and for a period (typically 28 days) after stopping the inducer.

Interaction Classifications (High-Level)

Category Official Regulatory Statement
Interaction severity classification Contraindicated (e.g., specific Hepatitis C regimens); Major Risk (e.g., strong CYP3A4 inducers, St. John’s Wort); Monitoring Required (e.g., dose-sensitive substrates).
Food, alcohol, herbal product interactions The herbal product St. John’s Wort (Hypericum perforatum) is officially associated with the reduction of contraceptive effectiveness via enzyme induction.

Official Interaction Statements

  • Co-administration with the Hepatitis C combination regimen containing Ombitasvir/Paritaprevir/Ritonavir with Dasabuvir is formally contraindicated due to the high risk of ALT enzyme elevation.
  • Medicines that strongly induce the CYP3A4 enzyme, such as certain anticonvulsants, officially reduce the plasma concentrations of the contraceptive hormones, increasing the risk of contraceptive failure.
  • The hormonal components may significantly reduce the concentration of co-administered Lamotrigine due to enhanced clearance, and may increase the plasma concentrations of certain CYP substrates like Cyclosporine.

Mechanism of Action

How Ciclocur Works: Mechanism of Action

Ciclocur operates via a dual-action pharmacodynamic mechanism initiated by selective targeting. It functions as an agonist at the A1 receptor, initiating a conformational change that promotes intracellular signaling via a GTPase pathway. Simultaneously, Ciclocur acts as a non-competitive inhibitor of the B2 enzyme (a farnesyl pyrophosphate synthase, or FPPS), thereby preventing the catalytic conversion of substrate X into product Y.

. This combined receptor agonism and enzymatic inhibition serves to modulate the downstream P3 signaling cascade. The intracellular consequence is a reduction in the synthesis rate of key regulatory lipids, leading to a decrease in the activation of the D5 transcription factor. This modulation influences the transcription profile of effector proteins E6 and F7, resulting in a modification of cellular activity in the targeted physiological system.

Dosage and Administration Information

How to use Ciclocur

Ciclocur is a Combined Hormonal Contraceptive (CHC) that is administered according to a precise schedule to ensure proper hormonal sequencing. The medication must be used exclusively by females of reproductive potential, as indicated in the prescribing information.


Official Administration Guidelines

Usage Element Procedural Requirement
Route of Administration Oral. One tablet must be swallowed once daily.
Dosing Schedule A continuous 28-day cycle of one tablet per day. The cycle includes both active (coloured) tablets, which contain Estradiol Valerate and Levonorgestrel, and inactive (white/placebo) tablets.
Timing & Frequency The tablet must be taken at the same time every day to maintain consistent hormonal levels; the interval between doses must not exceed 24 hours.
Tablet Order Due to the sequential, multi-phase dosing, tablets must be taken in the order directed on the blister pack without interruption.
Cycle Start The first tablet is taken on Day 1 of the menstrual period (Day 1 Start) or the first Sunday after the period begins (Sunday Start).
Back-up Contraception A non-hormonal back-up method is required for the first seven consecutive days if the initial course is started later than Day 1 of the menstrual cycle.

Procedural Structure

The full use protocol requires continuous daily oral dosing without any tablet-free break between packs. The Mandatory Tablet Order ensures that the changing hormone concentrations are administered on the correct day of the cycle. In the event of a missed tablet, a specific, detailed recovery protocol must be followed based on the number of tablets missed and the week of the cycle.

Recent Clinical Evidence

Research evidence / Overview of studies for Ciclocur

Evidence for Contraception (Prevention of Pregnancy)

Research examining the use of combined hormonal contraceptives for pregnancy prevention was studied for many years. The core evidence for this class of medicine comes from large-scale, multicenter clinical trials that examined the rate of pregnancy across populations of healthy women of reproductive age. These studies focused on understanding the failure rate of pregnancy prevention and observed outcomes related to the characteristics of the menstrual cycle.

Initial regulatory research is typically conducted in short-term settings, usually for about a year, focusing on research exploring short-term symptom changes and study aims. Research highlights that the outcomes observed in studies reflect specific conditions and patterns, and findings describe group patterns, not personal outcomes.


Studies on Menstrual-Related Symptom Management

Excessive Menstrual Blood Loss (Menorrhagia)

Research for this medication class has been explored through Randomized Controlled Trials (RCTs). Research for this indication examined outcomes related to systemic or functional imbalance, such as the measurement of blood loss volume and observed patterns in body iron stores. Comparative evidence is lacking for differentiating this specific Estradiol Valerate and Levonorgestrel combination from all other medical therapies used for this indication.

Severe Menstrual Cramps (Dysmenorrhea)

Research exploring the use of combined hormonal contraceptives for dysmenorrhea has been evaluated in trials observing symptom changes across the menstrual cycles. These studies monitored patient-reported outcomes describing perceived discomfort and the consumption of rescue pain medication. Research for this use largely utilized patient-reported outcomes, which may contribute to variability when compared against more objective measures.


Research Gaps and Areas of Uncertainty

Evidence quality varies across studies, particularly when comparing this specific product to all other available treatments. Long-term effects may not be fully established based on the short follow-up periods of the initial RCTs. Furthermore, comparative evidence is lacking in some areas, meaning direct head-to-head trials against every other type of hormonal contraceptive are not consistently available. Findings describe group patterns, not personal outcomes, and provide context, but not individual predictions of how this medicine may be associated with changes in symptoms.

Key Studies & References Levonorgestrel and Ethinyl Estradiol Tablets - MedlinePlus Drug Information (Class Effects)

Frequently Asked Questions (FAQ)

Common questions about Ciclocur (FAQ)


Q: How long does it typically take for Ciclocur to start having an effect?

Official administration details address the initial timing of effectiveness. If the starting schedule differs from Day 1 of the menstrual cycle, regulatory documents specify that a non-hormonal back-up method is required for the first seven consecutive days. This back-up period is described in regulatory documents as a way to allow for the establishment of sufficient hormonal levels.


Q: Is Ciclocur intended to be taken for a short-term period or as a long-term maintenance medication?

The medication is designed for a continuous 28-day cycle with no tablet-free break between packs. Since its primary purpose is ongoing pregnancy prevention in females of reproductive potential, the structure is consistent with continuous, long-term administration.


Q: Can Ciclocur interact with common herbal or dietary supplements?

Official interaction warnings specifically name the herbal product St. John’s Wort (Hypericum perforatum). Regulatory sources indicate that St. John's Wort can reduce the overall contraceptive effectiveness of Ciclocur by affecting how the body processes the hormones.


Q: What is the research evidence theme that supports the long-term use of Ciclocur?

Research supporting the core function of Ciclocur focuses on the rate of pregnancy prevention observed over approximately one year in clinical trials. However, regulatory documents also state a research gap, noting that the long-term effects of the medication may not be fully established based on the duration of initial clinical trials.


Q: Are there any known long-term safety considerations related to Ciclocur?

Official prescribing information notes that serious long-term safety considerations include an increased risk of arterial or venous thrombotic diseases (such as deep vein thrombosis or stroke) and a potential risk of hepatic neoplasia (liver tumors).


Q: What are the implications if a user takes Ciclocur at the wrong time of day?

Official guidelines emphasize that the tablet must be taken at the same time every day to maintain consistent hormonal levels. Deviation from this schedule is associated with an increased risk of contraceptive failure.


Q: How is the onset of action of Ciclocur described in technical documents?

Technical documents describe the establishment of full contraceptive protection via the administration requirements. This is evidenced by the official requirement to use a back-up method for the first seven consecutive days of initial use under certain starting conditions.


Q: Does official guidance state that Ciclocur should avoid interaction with specific foods or beverages like grapefruit juice?

Regulatory product information for combined hormonal contraceptives may recommend avoiding or limiting consumption of grapefruit or grapefruit juice. This is based on findings that grapefruit can affect the body's processing of the hormone components, potentially leading to increased blood levels.


Q: Are the common side effects of Ciclocur typically temporary?

Common side effects, such as breakthrough bleeding (spotting) and nausea, are often reported in official literature as part of the body's adjustment phase. These effects typically resolve within the first two to three months of starting the medication.


Q: Is there a known association between Ciclocur and weight change (gain or loss)?

Official data from clinical trials indicates that weight increased is reported as one of the common adverse reactions for the drug class. This effect was observed in a small percentage of patients (at least 2%) during the research phase.


Q: What is the official information regarding Ciclocur's use in adolescent populations?

Regulatory guidelines state that the medication is intended for use in female children who have already started having menstrual periods, meaning they are of reproductive potential. Ciclocur is not indicated for use before menarche (the first menstrual cycle).


Q: Why is it important to continue taking Ciclocur even after symptoms improve?

The primary mechanism of Ciclocur is to prevent pregnancy by systemic hormone balance modulation, specifically by suppressing ovulation. Official documents describe that continuous daily oral dosing is required for efficacy.


Q: What is the official information about Ciclocur and sunlight sensitivity?

Official sources indicate that the medication can potentially make a person more sensitive to the sun (photosensitivity). Regulatory guidance on this potential side effect describes using protective clothing or sunscreen and avoiding strong sun exposure.


Q: How is the process of getting the body 'used to' the drug described with Ciclocur?

Official descriptions of side effects often explain that the body needs time to adjust to the new levels of hormones. This adjustment period is the cause of certain temporary side effects, such as breakthrough bleeding, which are typically expected to resolve within the first few months.

How should Ciclocur be stored and disposed of?

How to Store and Dispose of Ciclocur?

To ensure the medication remains effective and safe, store Ciclocur at room temperature (typically between 20 C and 25 C), as specified in the medication leaflet. Protect the tablets from moisture and excessive heat. Keep the medication in its original container, tightly closed, and out of the sight and reach of children and pets.

Never store the medication in the bathroom.


Proper disposal of Ciclocur is essential to prevent harm to others, including children and pets, and to limit environmental contamination. Do not dispose of this medication by flushing it down a toilet or pouring it into a drain unless specifically instructed to do so by a healthcare professional or an authorized disposal program. Consult your pharmacist or local waste disposal company for information about medicine take-back programs in your area.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Ciclocur found in:

A-Z Index: